At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to =10% weight reduction with concomitant Taltz and ...

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced positive topline results from the pioneering TOGETHER-PsA Phase 3b trial.

Eli Lilly’s best-selling weight loss drug, Zepbound (tirzepatide), has scored again, this time in a late-stage trial alongside the company’s plaque psoriasis drug, Taltz (ixekizumab). During the Phase ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with concomitant ixekizumab and tirzepatide met PsA and weight reduction endpoints. Safety data ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced Thursday that its Phase 3b TOGETHER-PsA trial met its primary endpoint, showing that concomitant use of Taltz (ixekizumab) and Zepbound ...

On Thursday, Eli Lilly and Co. (NYSE: LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide ...

The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and ...